Implantica Sets Stockholm Capital Markets Day Following FDA Approval

The event, scheduled from 14:00 to 16:30 CEST at the Sergelkonferensen venue, serves as a pivotal platform for the Liechtenstein-based company to outline its commercial trajectory. CEO and founder Peter Forsell described the upcoming session as a defining moment for the firm, emphasizing the scale of the U.S. opportunity for a device targeting a condition that affects an estimated 1 billion people worldwide.

Beyond corporate strategy, the presentation will provide a practical look at the technology through the participation of surgeons and patients familiar with the RefluxStop system. Unlike traditional anti-reflux surgeries that rely on encircling the esophagus, the device aims to treat the root cause of GERD by restoring the lower esophageal sphincter to its natural position without applying constrictive pressure. Registration for the event is currently open via the company’s corporate affairs office.